Literature DB >> 20088979

Lactobacillus delbrueckii subsp lactis (strain CIDCA 133) resists the antimicrobial activity triggered by molecules derived from enterocyte-like Caco-2 cells.

A A Hugo1, G L De Antoni, P F Pérez.   

Abstract

AIMS: The aim of the present study was to assess the ability of a potentially probiotic strain to resist, in vitro, the effect of intestinal antimicrobial molecules. METHODS AND
RESULTS: Strain CIDCA 133 of Lactobacillus delbrueckii subsp lactis was studied. Lactobacillus delbrueckii subsp bulgaricus as well as other gram-positive and gram-negative bacteria were used for comparison purposes. The effect of different antimicrobial extracts was determined by diffusion assays, viable counts and growth kinetics. Human-defensins (h beta D1 and h beta D2) were also included in the study. Two types of cellular fractions from Caco-2 cells were tested: (i) cytosolic fractions, obtained by sonication of cultured human enterocytes and (ii) cationic fraction, obtained by batch extraction of the cytosolic fraction with a weak cation exchange resin. In addition, the effect of Caco-2-secreted factors was studied. Strain CIDCA 133 was neither inhibited by Caco-2 secreted, cytosolic nor cationic fractions. Of note, human-defensins were inactive against strain CIDCA 133. In contrast, a related lactobacilli: Lactobacilli delbrueckii subsp bulgaricus (strain CIDCA 331) and other species of gram-positive or gram-negative bacteria were strongly inhibited.
CONCLUSIONS: Strain CIDCA 133 is able to survive and grow in the presence of enterocyte-derived antimicrobial molecules. This ability is not a general property of lactobacilli. SIGNIFICANCE AND IMPACT OF THE STUDY: Results could provide a new insight into the mechanisms of the probiotic effect and encourage further studies on this field. Resistance to antimicrobial peptides can be relevant to understand the interaction of potentially probiotic strains with the host's immune system. This ability can be also relevant as a selection criterion for new probiotic strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20088979     DOI: 10.1111/j.1472-765X.2010.02796.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  5 in total

Review 1.  Probiotics, enteric and diarrheal diseases, and global health.

Authors:  Geoffrey A Preidis; Colin Hill; Richard L Guerrant; B S Ramakrishna; Gerald W Tannock; James Versalovic
Journal:  Gastroenterology       Date:  2010-11-12       Impact factor: 22.682

2.  Safety Evaluation of Lactobacillus delbrueckii subsp. lactis CIDCA 133: a Health-Promoting Bacteria.

Authors:  Luís Cláudio Lima de Jesus; Thiago de Jesus Sousa; Flávia Figueira Aburjaile; Vasco Azevedo; Nina Dias Coelho-Rocha; Rodrigo Profeta; Fernanda Alvarenga Lima Barroso; Mariana Martins Drumond; Pamela Mancha-Agresti; Ênio Ferreira; Bertram Brenig
Journal:  Probiotics Antimicrob Proteins       Date:  2021-08-17       Impact factor: 5.265

Review 3.  Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology.

Authors:  Holly Hardy; Jennifer Harris; Eleanor Lyon; Jane Beal; Andrew D Foey
Journal:  Nutrients       Date:  2013-05-29       Impact factor: 5.717

4.  Intake of Lactobacillus delbrueckii (pExu:hsp65) Prevents the Inflammation and the Disorganization of the Intestinal Mucosa in a Mouse Model of Mucositis.

Authors:  Fernanda Alvarenga Lima Barroso; Luís Cláudio Lima de Jesus; Camila Prosperi de Castro; Viviane Lima Batista; Ênio Ferreira; Renata Salgado Fernandes; André Luís Branco de Barros; Sophie Yvette Leclerq; Vasco Azevedo; Pamela Mancha-Agresti; Mariana Martins Drumond
Journal:  Microorganisms       Date:  2021-01-05

5.  Probiogenomics of Lactobacillus delbrueckii subsp. lactis CIDCA 133: In Silico, In Vitro, and In Vivo Approaches.

Authors:  Luís Cláudio Lima de Jesus; Mariana Martins Drumond; Flávia Figueira Aburjaile; Thiago de Jesus Sousa; Nina Dias Coelho-Rocha; Rodrigo Profeta; Bertram Brenig; Pamela Mancha-Agresti; Vasco Azevedo
Journal:  Microorganisms       Date:  2021-04-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.